Aspira Women's Health Inc. 8-K

What Happened
Aspira Women's Health Inc. announced on July 6, 2026 (agreement dated July 1, 2026) that it entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC (lead lender) and Agile Capital Funding, LLC (collateral agent). The lenders provided a secured term loan evidenced by a Subordinated Secured Promissory Note in the principal amount of $1,050,000. The note carries total interest charges of $441,000 if all payments are made on time and is scheduled to mature on January 26, 2027. The loan is expressly subordinated to all senior indebtedness.

Key Details

• Lenders: Agile Lending, LLC (lead) and Agile Capital Funding, LLC (collateral agent).
• Principal: $1,050,000; Interest charges: $441,000 (assuming timely payments); Maturity: January 26, 2027.
• Security: continuing security interest in substantially all of the company’s and co-borrowers’ personal property (accounts, inventory, equipment, general intangibles including IP, proceeds), with customary exclusions; financing statement to be filed only upon an event of default.
• Use of proceeds: refinance January loan debt and for general corporate purposes; loan is subordinated in right of payment to senior indebtedness; governed by Virginia law.

Why It Matters
This filing creates a new, short-term secured and subordinated debt obligation on Aspira’s balance sheet that increases near-term interest expense and adds creditor remedies (acceleration and collateral repossession) if default occurs. Because the note is subordinated, senior creditors remain ahead of this lender in priority; however, the grant of broad collateral and the potential filing of a financing statement upon default could affect the company’s secured asset availability. Retail investors should note the size, cost, maturity date (Jan 26, 2027), and purpose (refinancing prior debt) when assessing Aspira’s near-term liquidity and debt profile.